Oyster Point Pharma akcijos akcijų analizė | Akcijų kaina | Naujienos | OYST | US69242L1061 | A2PTTE

Data	Oyster Point Pharma Akcijų kaina
2023-01-12	11,17 undefined
2023-01-11	11,17 undefined

Data	Oyster Point Pharma Pajamos	Oyster Point Pharma EBIT	Oyster Point Pharma Pelnas
2026e	1,16 mlrd. undefined	−109,03 mln. undefined	−117,32 mln. undefined
2025e	475,01 mln. undefined	−80,59 mln. undefined	−84,83 mln. undefined
2024e	189,86 mln. undefined	−46,61 mln. undefined	−52,09 mln. undefined
2023e	98,15 mln. undefined	−85,23 mln. undefined	−94,74 mln. undefined
2022e	28,77 mln. undefined	−158,53 mln. undefined	−172,94 mln. undefined
2021	24,54 mln. undefined	−96,66 mln. undefined	−100,66 mln. undefined
2020	0 undefined	−70,99 mln. undefined	−70,52 mln. undefined
2019	0 undefined	−47,30 mln. undefined	−45,71 mln. undefined
2018	0 undefined	−16,74 mln. undefined	−16,50 mln. undefined
2017	0 undefined	−5,68 mln. undefined	−19,14 mln. undefined

	Pajamos	EBIT	Pelnas
2017	0 USD	−5,68 mln. USD	−19,14 mln. USD
2018	0 USD	−16,74 mln. USD	−16,50 mln. USD
2019	0 USD	−47,30 mln. USD	−45,71 mln. USD
2020	0 USD	−70,99 mln. USD	−70,52 mln. USD
2021	24,54 mln. USD	−96,66 mln. USD	−100,66 mln. USD
2022e	28,77 mln. USD	−158,53 mln. USD	−172,94 mln. USD
2023e	98,15 mln. USD	−85,23 mln. USD	−94,74 mln. USD
2024e	189,86 mln. USD	−46,61 mln. USD	−52,09 mln. USD
2025e	475,01 mln. USD	−80,59 mln. USD	−84,83 mln. USD
2026e	1,16 mlrd. USD	−109,03 mln. USD	−117,32 mln. USD

2017	2018	2019	2020	2021	2022e	2023e	2024e	2025e	2026e
0	0	0	0	0,02	0,03	0,10	0,19	0,48	1,16
-	-	-	-	-	16,67	250,00	92,86	151,32	144,21
-	-	-	-	95,83	-	-	-	-	-
0	0	0	0	23,00	0	0	0	0	0
−5,00	−16,00	−47,00	−70,00	−96,00	−158,00	−85,00	−46,00	−80,00	−109,00
-	-	-	-	−400,00	−564,29	−86,73	−24,34	−16,84	−9,40
−19,00	−16,00	−45,00	−70,00	−100,00	−172,00	−94,00	−52,00	−84,00	−117,00
-	−15,79	181,25	55,56	42,86	72,00	−45,35	−44,68	61,54	39,29
20,61	20,61	21,37	24,13	26,04	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021

22,30	5,20	139,10	192,60	193,37
0	0	0	0	6,66
0	0	0	0	0
0	0	0	0	6,09
0,90	0,40	3,00	3,80	9,14
23,20	5,60	142,10	196,40	215,25
0	0,10	1,00	1,50	5,40
0	0	0	0	886,00
0	0	0	0	0
0	0	0	0	0
0	0	0	0	0
0	0	0,10	0,10	1,08
0	0,10	1,10	1,60	7,37
23,20	5,70	143,20	198,00	222,62

43,00	43,00	0	0	0,03
0,10	0,30	221,50	341,40	354,92
−22,00	−38,50	−84,20	−154,80	−255,41
0	0	0	0	0
0	0	0	0	0
21,10	4,80	137,30	186,60	99,54
0,40	0,50	0,50	2,30	6,50
1,60	0,50	4,90	8,70	22,29
0	0	0	0	0
0	0	0	0	0
0	0	0	0	16,00
2,00	1,00	5,40	11,00	28,80
0	0	0	0	89,82
0	0	0	0	0
0	0	0,50	0,30	4,46
0	0	0,50	0,30	94,28
2,00	1,00	5,90	11,30	123,08
23,10	5,80	143,20	197,90	222,62

2017	2018	2019	2020	2021
−6,00	−16,00	−45,00	−70,00	−100,00
0	0	0	0	0
0	0	0	0	0
0	0	1,00	5,00	−2,00
1,00	0	3,00	6,00	13,00
0	0	0	0	2,00
0	0	0	0	0
−4,00	−17,00	−40,00	−58,00	−89,00
0	0	0	0	−1,00
0	0	0	0	−1,00
0	0	0	0	0
0	0	0	0	0
4,00	0	0	0	0
21,00	0	174,00	112,00	96,00
26,00	0	174,00	112,00	91,00
-	-	-	-	−4,00
0	0	0	0	0
21,00	−17,00	133,00	53,00	0
−4,67	−17,08	−41,02	−59,10	−90,86
0	0	0	0	0

Oyster Point Pharma Bruto marža	Oyster Point Pharma Pelnas-martža	Oyster Point Pharma EBIT marža	Oyster Point Pharma Pelnas-martža
2026e	93,79 %	−9,39 %	−10,11 %
2025e	93,79 %	−16,97 %	−17,86 %
2024e	93,79 %	−24,55 %	−27,44 %
2023e	93,79 %	−86,83 %	−96,52 %
2022e	93,79 %	−550,99 %	−601,09 %
2021	93,79 %	−393,88 %	−410,20 %
2020	93,79 %	0 %	0 %
2019	93,79 %	0 %	0 %
2018	93,79 %	0 %	0 %
2017	93,79 %	0 %	0 %

	Bruto marža	EBIT marža	Pelnas-martža
2017	93,79 %	0 %	0 %
2018	93,79 %	0 %	0 %
2019	93,79 %	0 %	0 %
2020	93,79 %	0 %	0 %
2021	93,79 %	−393,88 %	−410,20 %
2022e	93,79 %	−550,99 %	−601,09 %
2023e	93,79 %	−86,83 %	−96,52 %
2024e	93,79 %	−24,55 %	−27,44 %
2025e	93,79 %	−16,97 %	−17,86 %
2026e	93,79 %	−9,39 %	−10,11 %

Data	Oyster Point Pharma Pardavimai vienai akcijai	Oyster Point Pharma EBIT vienai akcijai	Oyster Point Pharma Pelnas vienai akcijai
2026e	43,24 undefined	0 undefined	−4,37 undefined
2025e	17,69 undefined	0 undefined	−3,16 undefined
2024e	7,07 undefined	0 undefined	−1,94 undefined
2023e	3,66 undefined	0 undefined	−3,53 undefined
2022e	1,07 undefined	0 undefined	−6,44 undefined
2021	0,94 undefined	−3,71 undefined	−3,87 undefined
2020	0 undefined	−2,94 undefined	−2,92 undefined
2019	0 undefined	−2,21 undefined	−2,14 undefined
2018	0 undefined	−0,81 undefined	−0,80 undefined
2017	0 undefined	−0,28 undefined	−0,93 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2017	0 USD	−0,28 USD	−0,93 USD
2018	0 USD	−0,81 USD	−0,80 USD
2019	0 USD	−2,21 USD	−2,14 USD
2020	0 USD	−2,94 USD	−2,92 USD
2021	0,94 USD	−3,71 USD	−3,87 USD
2022e	1,07 USD	0 USD	−6,44 USD
2023e	3,66 USD	0 USD	−3,53 USD
2024e	7,07 USD	0 USD	−1,94 USD
2025e	17,69 USD	0 USD	−3,16 USD
2026e	43,24 USD	0 USD	−4,37 USD

Segmente	2021
License revenue - related party	18,39 mln. USD
Milestone revenue - related party	5,00 mln. USD
Product revenue, net	1,15 mln. USD
TYRVAYA Nasal Spray	1,20 mln. USD

	License revenue - related party	Milestone revenue - related party	Product revenue, net	TYRVAYA Nasal Spray
2021	18,39 mln. USD	5,00 mln. USD	1,15 mln. USD	1,20 mln. USD

	Akcijų skaičius
2017	20,61 mln. Aktien
2018	20,61 mln. Aktien
2019	21,37 mln. Aktien
2020	24,13 mln. Aktien
2021	26,04 mln. Aktien
2022e	26,04 mln. Aktien
2023e	26,04 mln. Aktien
2024e	26,04 mln. Aktien
2025e	26,04 mln. Aktien
2026e	26,04 mln. Aktien

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2022-09-30	−1,56	−1,37 (11,98 %)	2022 Q3
2022-06-30	−1,69	−1,87 (−10,44 %)	2022 Q2
2022-03-31	−1,78	−1,80 (−1,27 %)	2022 Q1
2021-12-31	−1,42	−1,61 (−13,56 %)	2021 Q4
2021-09-30	−1,18	−0,68 (42,36 %)	2021 Q3
2021-06-30	−0,86	−0,85 (1,57 %)	2021 Q2
2021-03-31	−0,93	−0,73 (21,35 %)	2021 Q1
2020-12-31	−0,80	−0,86 (−7,18 %)	2020 Q4
2020-09-30	−0,75	−0,63 (16,16 %)	2020 Q3
2020-06-30	−0,82	−0,66 (19,62 %)	2020 Q2
2020-03-31	−1,08	−0,77 (28,78 %)	2020 Q1
2019-12-31	−0,59	−1,41 (−138,34 %)	2019 Q4
2019-09-30	−0,52	−8,10 (−1 457,09 %)	2019 Q3

%	Pavadinimas	Akcijos	Pokytis	Data
7,61544 %	RTW Investments L.P.	2 044 312	−14 192	2022-09-30
6,72540 %	Point72 Asset Management, L.P.	1 805 387	−83 709	2022-09-30
6,14028 %	Paradigm BioCapital Advisors LP	1 648 316	185 740	2022-09-30
3,87278 %	Kohlberg Kravis Roberts & Co. L.P.	1 039 622	0	2022-09-30
22,07279 %	New Enterprise Associates (NEA)	5 925 287	0	2022-11-07
2,89457 %	Telemark Asset Management, LLC	777 026	0	2022-09-30
2,10419 %	GW&K Investment Management, LLC	564 856	100 473	2022-09-30
13,62531 %	Versant Ventures	3 657 618	−201 474	2022-01-05
10,31350 %	Invus Financial Advisors, LLC	2 768 586	0	2022-09-30
1,89908 %	Cowen & Co., LLC	509 794	0	2022-09-30
1,59101 %	The Vanguard Group, Inc.	427 095	−239 620	2022-09-30
1,21346 %	BlackRock Institutional Trust Company, N.A.	325 746	−3 351	2022-09-30
1,10287 %	Citadel Advisors LLC	296 058	72 593	2022-09-30
0,78303 %	Laurion Capital Management LP	210 200	0	2022-09-30
0,75683 %	JP Morgan Asset Management	203 167	87 671	2022-09-30
0,57804 %	Geode Capital Management, L.L.C.	155 171	33 231	2022-09-30
0,51402 %	BlackRock Financial Management, Inc.	137 984	−21 673	2022-09-30
0,44188 %	Murray (Mark Anthony)	118 620	3 573	2022-06-06
0,44091 %	Morgan Stanley & Co. LLC	118 360	1 368	2022-09-30
0,39734 %	Creative Planning, Inc.	106 662	0	2022-09-30
0,39692 %	Millennium Management LLC	106 551	−28 087	2022-09-30
0,37221 %	HSBC Private Bank (Suisse) S.A.	99 916	0	2022-08-31
0,35645 %	Goldman Sachs & Company, Inc.	95 686	−152	2022-09-30
0,31365 %	Nau (Jeffrey)	84 197	−8 938	2022-12-01
0,28843 %	Barclays Bank PLC	77 427	−25 589	2022-09-30
0,21919 %	Link (William J)	58 839	3 466	2021-06-07
0,18229 %	State Street Global Advisors (US)	48 934	0	2022-09-30
0,17712 %	Lochner (Daniel J.)	47 547	−3 258	2022-12-01
0,15615 %	HRT Financial LP	41 917	41 917	2022-09-30
0,15240 %	Tower Research Capital LLC	40 911	38 093	2022-09-30
0,14901 %	Bridgeway Capital Management, LLC	40 000	0	2022-09-30
0,13726 %	Wildcat Capital Management, LLC	36 847	0	2022-09-30
0,11772 %	Northern Trust Investments, Inc.	31 600	3 664	2022-09-30
0,09532 %	Weisner Aimee S	25 589	3 573	2022-06-06
0,08394 %	Morgan Stanley Smith Barney LLC	22 532	686	2022-09-30
0,08265 %	Susquehanna International Group, LLP	22 187	−35 167	2022-09-30
0,07518 %	Walleye Capital LLC	20 182	20 182	2022-09-30
0,07028 %	Jane Street Capital, L.L.C.	18 867	18 867	2022-09-30
0,06245 %	Assenagon Asset Management S.A.	16 764	530	2022-10-31
0,05687 %	BlackRock Investment Management (UK) Ltd.	15 266	0	2022-09-30
0,05308 %	Qube Research & Technologies Ltd	14 248	14 248	2022-09-30
0,05279 %	Ergoteles Capital	14 172	−20 580	2022-09-30
0,05011 %	BofA Global Research (US)	13 451	−3 419	2022-09-30
0,04869 %	Atieh (Michael G)	13 071	3 573	2022-06-06
0,04679 %	HarbourVest Partners, L.L.C.	12 560	0	2022-09-30
0,04507 %	Kestra Advisory Services, LLC	12 100	200	2022-09-30
0,04459 %	Coastal Bridge Advisors, LLC	11 970	0	2022-09-30
0,04352 %	BlackRock Advisors (UK) Limited	11 683	432	2022-11-30
0,04218 %	BlackRock Asset Management Ireland Limited	11 322	−103	2022-09-30
0,04072 %	Ozawa (Clare)	10 931	3 573	2022-06-06
0,04036 %	BNY Mellon Asset Management	10 834	10 834	2022-09-30
0,04025 %	Snisarenko (John)	10 806	−8 294	2022-03-31
0,03911 %	ACG Wealth Inc.	10 500	−4 214	2022-09-30
0,03843 %	BlackRock Investment Management, LLC	10 317	−851	2022-09-30
0,03790 %	Tsai (Benjamin)	10 173	3 573	2022-06-06
0,03790 %	Behbahani (Ali)	10 173	3 573	2022-06-06
0,03725 %	Cherry Creek Investment Advisors, Inc	10 000	0	2022-09-30
0,03166 %	ACT Capital Management, L.L.C.	8 500	0	2022-09-30
0,01949 %	Simplex Trading, LLC	5 233	−3 112	2022-09-30
0,01946 %	Eliades (George Christopher)	5 223	3 573	2022-06-06
0,01945 %	Granahan Investment Management, Inc.	5 221	−283	2021-06-30
0,01797 %	Victory Capital Management Inc.	4 823	0	2022-09-30
0,01714 %	T. Rowe Price Associates, Inc.	4 600	0	2022-09-30
0,01490 %	Rockefeller Capital Management	4 000	4 000	2022-09-30
0,01354 %	Parametric Portfolio Associates LLC	3 635	−1 200	2022-09-30
0,01331 %	Santel (Donald J)	3 573	3 573	2022-06-06
0,01288 %	Northern Trust Global Investments	3 457	0	2022-09-30
0,01096 %	Dimensional Fund Advisors, Ltd.	2 942	−6 867	2022-10-31
0,01029 %	Cubist Systematic Strategies, LLC	2 761	0	2022-09-30
0,00992 %	UBS Financial Services, Inc.	2 664	417	2022-09-30
0,00979 %	Aperio Group, LLC	2 627	−121	2022-09-30
0,00840 %	ProShare Advisors LLC	2 256	0	2022-10-31
0,00838 %	Advisor Group, Inc	2 250	2 000	2022-09-30
0,00807 %	Lord, Abbett & Co. LLC	2 165	0	2022-09-30
0,00764 %	GPS Wealth Strategies Group, LLC	2 052	−82	2022-09-30
0,00639 %	J.P. Morgan Securities plc	1 715	719	2022-09-30
0,00632 %	Zürcher Kantonalbank (Asset Management)	1 697	0	2022-09-30
0,00559 %	RBC Capital Markets Wealth Management	1 500	0	2022-09-30
0,00558 %	City National Rochdale, LLC	1 497	0	2022-09-30
0,00510 %	Group One Trading, L.P.	1 369	−877	2022-09-30
0,00509 %	Amalgamated Financial Corp.	1 366	1 366	2022-03-31
0,00496 %	PGIM Quantitative Solutions LLC	1 332	0	2021-09-30
0,00414 %	BlackRock Japan Co., Ltd.	1 111	−2 812	2022-09-30
0,00410 %	Gibson Wealth Advisors LLC	1 100	0	2022-09-30
0,00303 %	Huntington Private Financial Group	813	−324	2022-09-30
0,00264 %	Principal Funds, Inc.	709	−233	2022-04-30
0,00248 %	Mirae Asset Global Investments Co., Ltd.	666	6	2022-07-31
0,00231 %	GF Fund Management Co., Ltd.	619	347	2022-06-30
0,00221 %	Mackenzie Financial Corporation	594	−77	2022-09-30
0,00196 %	Invesco Capital Management LLC	526	−25	2022-10-31
0,00180 %	Manulife Investment Management (North America) Limited	482	0	2022-09-30
0,00168 %	Westfield Capital Management Company, L.P.	452	0	2021-09-30
0,00117 %	Citi Investment Research (US)	314	−198	2022-09-30
0,00109 %	Fidelity Management & Research Company LLC	293	0	2022-09-30
0,00094 %	China Universal Asset Management Co., Ltd.	251	251	2022-09-30
0,00080 %	Capital Investment Trust Corporation	216	0	2022-09-30
0,00075 %	Geneos Wealth Management Inc	200	0	2022-09-30
0,00056 %	Tinkoff Capital OOO	150	150	2021-12-31
0,00054 %	Avantis Investors	144	78	2022-09-30
0,00042 %	Wells Fargo Bank, N.A.	112	26	2022-09-30

Pavadinimas	Santykis	Dviejų savaičių koreliacija	Vieno mėnesio koreliacija	Trymėnesio koreliacija	Šešių mėnesių koreliacija	Vienmečio koreliacija	Dviejų metų koreliacija
Pfizer	TiekėjasKlientas	0,40	0,76	-0,21	0,47	-0,39	-0,81

What values and corporate philosophy does Oyster Point Pharma represent?

Oyster Point Pharma Inc is committed to upholding a set of core values and a corporate philosophy that guides its operations. The company places a strong emphasis on innovation and scientific excellence to develop novel therapies. Oyster Point Pharma Inc also prioritizes patient-centricity by striving to meet the unmet needs of individuals with ocular surface diseases and ocular neurology disorders. The company believes in fostering a culture of collaboration and teamwork, aiming to build lasting relationships with patients, healthcare professionals, and stakeholders. Oyster Point Pharma Inc continuously strives to deliver value to its shareholders while maintaining high ethical standards and transparency in all aspects of its business.

In which countries and regions is Oyster Point Pharma primarily present?

Oyster Point Pharma Inc is primarily present in the United States.

What significant milestones has the company Oyster Point Pharma achieved?

Oyster Point Pharma Inc has achieved several significant milestones in its journey. The company successfully completed a Phase 2b clinical trial for its lead product candidate, OC-01 nasal spray, demonstrating positive results in treating dry eye disease. Oyster Point Pharma Inc also received Fast Track designation from the U.S. FDA for OC-01, highlighting the potential of this therapeutic approach. Furthermore, the company obtained FDA approval to initiate a Phase 3 clinical trial for OC-01, showcasing its commitment to advancing this novel treatment option for patients. Oyster Point Pharma Inc's achievements demonstrate its dedication to developing innovative solutions for ocular surface diseases.

What is the history and background of the company Oyster Point Pharma?

Oyster Point Pharma Inc is a pharmaceutical company specializing in the development and commercialization of therapies for ocular surface diseases. Founded in 2015, the company aims to address the unmet medical needs of patients suffering from dry eye disease. Their innovative therapies target neuroreceptors in the eye to stimulate tear production and improve ocular surface health. Oyster Point Pharma Inc has conducted extensive research and clinical trials to support the effectiveness and safety of their products. With a dedicated team of experts in the field, the company is committed to advancing treatment options for patients with ocular surface diseases, including dry eye.

Who are the main competitors of Oyster Point Pharma in the market?

The main competitors of Oyster Point Pharma Inc in the market are pharmaceutical companies that focus on developing therapies for dry eye disease and other ocular surface disorders. Some notable competitors include Novartis AG, Johnson & Johnson, Allergan, Alcon, and Santen Pharmaceutical Co., Ltd. These companies, like Oyster Point Pharma Inc, strive to address the unmet needs of patients suffering from ocular surface diseases through innovative treatments and therapies.

In which industries is Oyster Point Pharma primarily active?

Oyster Point Pharma Inc is primarily active in the pharmaceutical industry.

What is the business model of Oyster Point Pharma?

Oyster Point Pharma Inc's business model focuses on the development and commercialization of innovative therapies for ocular surface diseases. The company is dedicated to providing effective and safe treatment options for individuals suffering from conditions such as dry eye disease. Oyster Point Pharma Inc leverages its expertise in neurostimulation and ophthalmology to develop novel therapies that target the underlying causes of these ocular surface diseases. By addressing the unmet needs of patients, Oyster Point Pharma Inc aims to improve the quality of life and vision for individuals worldwide.

Koks yra Oyster Point Pharma 2024 KGV?

Oyster Point Pharma KGV yra −5,58.

Koks Oyster Point Pharma 2024 KUV?

Oyster Point Pharma KUV yra 1,53.

Koks yra Oyster Point Pharma AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Oyster Point Pharma yra 3/10.

Koks yra Oyster Point Pharma 2024 pajamų dydis?

tikėtina Oyster Point Pharma pardavimai yra 189,86 mln. USD.

Kokia yra Oyster Point Pharma 2024 pelnas?

tikėtina Oyster Point Pharma pelnas yra −52,09 mln. USD.

Ką daro Oyster Point Pharma?

Oyster Point Pharma Inc is an innovative biopharmaceutical company focused on developing therapeutic treatments for patients with ophthalmological diseases. The company's main focus is on developing medications for the treatment of patients with Dry Eye and other anterior eye diseases. The business model of Oyster Point Pharma is based on identifying new treatment options for patients suffering from Dry Eye symptoms. The company has developed a range of patented technologies that allow it to quickly and cost-effectively develop and bring new medications to market. The company is divided into two business areas: Research and Development, and Marketing and Sales. In the Research and Development area, Oyster Point Pharma collaborates closely with a network of scientists and experts to develop new medications that are safe and effective. The company utilizes state-of-the-art technology and research platforms to quickly gain new insights and develop effective medications. In the Marketing and Sales area, Oyster Point Pharma focuses on successfully placing and selling its medications in the market. The company works with a network of distribution partners to ensure that its products are available in all key markets. The company focuses on supporting and training its distribution partners to ensure they are able to sell effectively and successfully. One key product of Oyster Point Pharma is OC-01 (varenicline), a medication for the treatment of patients with Dry Eye. The medication is a synthetic analog of acetylcholine, a naturally occurring neurotransmitter responsible for increasing tear fluid and salivary gland secretion. By increasing acetylcholine levels in the patient's body, OC-01 increases tear fluid, reducing Dry Eye symptoms. Oyster Point Pharma also has other promising drug candidates in the pipeline, including the medication OC-02 (nimento) for the treatment of anterior eye diseases, and OC-03, which is in preclinical development for the treatment of posterior eye diseases (macular degeneration). Overall, Oyster Point Pharma's business model is focused on becoming a leading provider of therapeutic treatments for patients with ophthalmological diseases. The company relies on advanced product innovation in research and development and an effective marketing and sales strategy. With its pipeline of promising drug candidates, Oyster Point Pharma has the potential to revolutionize the market for ophthalmic medications.

Kokia yra Oyster Point Pharma dividendė?

Oyster Point Pharma moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Oyster Point Pharma moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Oyster Point Pharma arba įmonė dividendų nemoka.

Kas yra Oyster Point Pharma ISIN?

Oyster Point Pharma ISIN yra US69242L1061.

Kas yra Oyster Point Pharma WKN?

Oyster Point Pharma WKN yra A2PTTE.

Kas yra Oyster Point Pharma Tickeris?

Oyster Point Pharma akcijų simbolis yra OYST.

Kiek dividendų moka Oyster Point Pharma?

Per paskutinius 12 mėnesių Oyster Point Pharma išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Oyster Point Pharma tikėtina išmokės dividendus, kurie sudarys 0 USD.

Kokia yra Oyster Point Pharma dividendų grąža?

Oyster Point Pharma šiuo metu yra dydžio dividendų grąža.

Kada Oyster Point Pharma moka dividendus?

Oyster Point Pharma moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra Oyster Point Pharma dividendų išmokėjimas?

Oyster Point Pharma per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Oyster Point Pharma dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra Oyster Point Pharma?

Oyster Point Pharma priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Oyster Point Pharma kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Oyster Point Pharma dividendą nuo 2024-09-26, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-09-26.

Kada Oyster Point Pharma paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2024-09-26.

Kokia buvo Oyster Point Pharma dividendų suma 2023 metais?

2023 metais Oyster Point Pharma išmokėjo 0 USD dividendų.

Kokia valiuta Oyster Point Pharma moka dividendus?

Oyster Point Pharma dividendai yra mokami USD.

Oyster Point Pharma Akcijų kodas	Oyster Point Pharma FIGI
OYST:UB	BBG00QHW94K3
OYST:UX	BBG00QHW94N0

Padaryk geriausias savo gyvenimo investicijas fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kursas

Akcijos kaina

Akcijų kodasOYST

ISINUS69242L1061

VVPA2PTTE

Oyster Point Pharma akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

Oyster Point Pharma Akcijų istorija

Oyster Point Pharma akcijų apyvarta, EBIT, pelnas US69242L1061 · A2PTTE

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Oyster Point Pharma Pajamų, pelno ir EBIT istorija.

Oyster Point Pharma Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Oyster Point Pharma Akcijos Maržos US69242L1061 · A2PTTE

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Oyster Point Pharma Maržų istorija

Oyster Point Pharma akcijos apyvarta, EBIT, pelnas vienai akcijai US69242L1061 · A2PTTE

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Oyster Point Pharma Pardavimų, pelno ir EBIT istorija vienai akcijai

Oyster Point Pharma akcija ir akcijų analizė

Oyster Point Pharma Pajamos pagal segmentą US69242L1061 · A2PTTE

Pardavimai pagal segmentą

Pardavimų pagal segmentą apžvalga

Interpretacija ir panaudojimas

Investavimo strategija

Oyster Point Pharma Pajamos pagal segmentą

Oyster Point Pharma vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

Oyster Point Pharma įvertinimas pagal istorinį P/E, EBIT ir P/S

Oyster Point Pharma akcijų skaičius US69242L1061 · A2PTTE

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Oyster Point Pharma Pelno prognozės

Oyster Point Pharma Pelnų staigmenos

Oyster Point Pharma akcijos akcininkų struktūra

Oyster Point Pharma Valdyba ir Priežiūros taryba

Oyster Point Pharma Tiekimo grandinė.

Dažnai užduodami klausimai apie Oyster Point Pharma akciją

What values and corporate philosophy does Oyster Point Pharma represent?

Padaryk geriausias savo gyvenimo investicijas
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Akcijų kodas
OYST

ISIN
US69242L1061

VVP
A2PTTE